Castle Biosciences CSTL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $83.68M-4.9% | $87.01M+0.8% | $83.04M-3.2% | $86.19M-0.9% | $87.99M+20.6% | ||
| $20.53M+25.3% | $18.32M+13.2% | $18.7M+19.8% | $17.63M+21.4% | $16.38M+17.9% | ||
| $14.43M+14.6% | $13.52M+14.8% | $12.96M+5.2% | $12.79M-9.5% | $12.59M-8.8% | ||
| $64.9M+10.7% | $56.73M+13.5% | $55.91M+10.7% | $58.07M+13.7% | $58.62M+20.9% | ||
| $2.23M-92.1% | $2.28M-47.6% | $2.28M+0.2% | $1.96M-12.7% | $28.33M+1,161% | ||
| -$18.41M+34.1% | -$3.83M-194% | -$6.8M-234% | -$4.25M-185% | -$27.93M-410% | ||
| -22%+9.7pp | -4.4%-9.1pp | -8.2%-14.1pp | -4.9%-10.7pp | -31.7%-24.2pp | ||
| $134K+688% | $24K-73.9% | $24K-88.1% | $21K-92.2% | $17K+21.4% | ||
| $2.55M-17.9% | $2.9M-14.1% | $2.83M-16.8% | $2.94M-6.4% | $3.1M+3.4% | ||
| -$439K— | $96K— | $48K— | $0— | $0— | ||
| $2.02M+242% | —— | —— | —— | -$1.43M-1,127% | ||
| $109K+126% | -$382K— | $115K-98.1% | -$4.67M-351% | -$423K-1,040% | ||
| -$14.52M+43.8% | -$2.33M-124% | -$501K-122% | $4.52M-49.3% | -$25.85M-920% | ||
| -17.4%+12.0pp | -2.7%-13.8pp | -0.6%-3.2pp | 5.2%-5.0pp | -29.4%-25.9pp | ||
| -$0.49+45.6% | -$0.07-122% | -$0.02-125% | $0.15-51.6% | -$0.90-900% | ||
| -$0.49+45.6% | -$0.07-120% | -$0.02-125% | $0.16-50.0% | -$0.90-900% | ||
| 29.9M+4.5% | 29M-0.9% | 29.1M-1.1% | 29.5M+2.8% | 28.6M+4.1% | ||
| 29.9M+4.5% | 29M+4.4% | 29.1M+4.4% | 28.9M+4.6% | 28.6M+4.1% | ||
| $102.09M-11.9% | $90.84M+10.4% | $89.85M+11.3% | $90.44M+10.3% | $115.92M+47.8% | ||
| -$439K— | $96K— | $48K— | $0— | $0— | ||
| $83.68M-4.9% | $87.01M+0.8% | $83.04M-3.2% | $86.19M-0.9% | $87.99M+20.6% | ||
| -$18.41M+34.1% | -$3.83M-194% | -$6.8M-234% | -$4.25M-185% | -$27.93M-410% | ||
| -$14.48M-889% | -$50K-101% | -$2.99M-135% | -$837K-110% | $1.84M+186% | ||
| -$14.48M-889% | -$50K-101% | -$2.99M-135% | -$837K-110% | $1.84M+186% | ||
| -17.3%-19.4pp | -0.1%-11.4pp | -3.6%-13.6pp | -1%-10.6pp | 2.1%+5.0pp | ||
| -$18.41M+34.1% | -$3.83M-194% | -$6.8M-234% | -$4.25M-185% | -$27.93M-410% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Castle Biosciences's revenue?
- Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.
- Is Castle Biosciences profitable?
- Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.
- What are Castle Biosciences's profit margins?
- Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.
- What is Castle Biosciences's earnings per share?
- Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.
- Where does Castle Biosciences's income statement data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
